PDF(Pubmed)
Abstract：
Colorectal cancer (CRC) is a common, and deadly disease. Despite the improved knowledge on CRC heterogeneity and advances in the medical sciences, there is still an urgent need to cope with the challenges and side effects of common treatments for the disease. Natural products (NPs) have always been of interest for the development of new medicines. Actinobacteria are known to be prolific producers of a wide range of bioactive NPs, and scientific evidence highlights their important protective role against CRC. This review is a holistic picture on actinobacter-derived cytotoxic compounds against CRC that provides a good perspective for drug development and design in near future. This review also describes the chemical structure of 232 NPs presenting anti-CRC activity with the being majority of quinones, lactones, alkaloids, peptides, and glycosides. The study reveals that most of these NPs are derived from marine actinobacteria followed by terrestrial and endophytic actinobacteria, respectively. They are predominantly produced by Streptomyces, Micromonospors, Saliniospors and Actinomadura, respectively, in which Streptomyces, as the predominant contributor generating over 76% of compounds exclusively. Besides it provides a valuable snapshot of the chemical structure-activity relationship of compounds, highlighting the presence or absence of some specific atoms and chemical units in the structure of compounds can greatly influence their biological activities. To the best of our knowledge, this is the first comprehensive review on natural actinobacterial compounds affecting different types of CRC. Our study reveals that the high diversity of actinobacterial strains and their NPs derivatives, described here provides a new perspective and direction for the production of new anti-CRC drugs and paves the way to innovation for drugs discovery in the future. The knowledge obtain from this review can help us to understand the pivotal application of actinobacteria in future drugs development.
摘要：
结直肠癌(CRC)是一种常见的,致命的疾病。尽管对CRC异质性的认识和医学科学的进步，仍然迫切需要应对这种疾病的常见治疗方法的挑战和副作用。天然产物（NPs）一直是新药开发的兴趣。已知放线菌是多种生物活性NP的多产生产者，科学证据强调了它们对CRC的重要保护作用。这篇综述是针对CRC的放线菌衍生的细胞毒性化合物的整体图景，为不久的将来的药物开发和设计提供了良好的前景。这篇综述还描述了232个具有抗CRC活性的NP的化学结构，其中大多数是醌，内酯,生物碱，肽，和糖苷。研究表明，这些NPs大多来自海洋放线菌，其次是陆地和内生放线菌，分别。它们主要由链霉菌产生，微单体,Saliniospors和Actinomadura，分别,其中链霉菌，作为主要贡献者，仅产生超过76%的化合物。此外，它还提供了化合物化学结构-活性关系的有价值的快照，突出化合物结构中某些特定原子和化学单元的存在或不存在会极大地影响其生物活性。据我们所知,这是对影响不同类型CRC的天然放线菌化合物的首次全面综述.我们的研究表明，放线菌菌株及其NPs衍生物的高多样性，本文的描述为新的抗CRC药物的生产提供了新的视角和方向，并为未来的药物发现创新铺平了道路。从这篇综述中获得的知识可以帮助我们了解放线菌在未来药物开发中的关键应用。
